Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Israel-based XTL Biopharmaceuticals has dropped the development of an experimental hepatitis C drug after a phase I trial failed to show a statistically significant difference between the compound and placebo.
Subscribe to our email newsletter
The trial evaluated the safety, tolerability and antiviral activity of single and multiple doses of the drug, XTL-2125, with 56 patients. Although XTL-2125 was generally well tolerated, the company said, HCV-RNA viral load reductions in patients treated with XTL-2125 were not significantly different from those observed in the placebo group. Based on these results, XTL has decided to suspend further development of XTL-2125.
However, the company said that its XTL-DOS program looked “promising” for hepatitis C, and was expecting to submit an IND for a novel drug from the studies in 2007. XTL also said that it would continue to pursue opportunities through in-licensing and acquisition of additional clinical-stage products.